Indium In-111 pentetate
Identification
- Name
- Indium In-111 pentetate
- Accession Number
- DB09425
- Description
Indium In-111 pentetate disodium is a radioactive diagnostic indicated for use in radionuclide cisternography. Decay of In-111 by electron capture allows for detection with a gamma camera for visualization of the brain and spinal column.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Indium In-111 pentetate (DB09425)
- Weight
- Average: 501.23
Monoisotopic: 501.019979533 - Chemical Formula
- C14H20InN3O10
- Synonyms
- Indium (111In) pentetic acid
- Indium In 111 pentetate
- Indium In-111 pentetate
Pharmacology
- Indication
Pentetate Indium Disodium In 111 is recommended for use in radionuclide cisternography.
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
Decay of In-111 by electron capture allows for detection with a gamma camera for visualization of the brain and spinal column.
- Absorption
After intrathecal administration, the radiopharmaceutical is absorbed from the subarachnoid space as described below, and the remainder flows superiorly to the basal cisterns within 2 to 4 hours and subsequently will be apparent in the Sylvian cisterns, the interhemispheric cisterns, and over the cerebral convexities. In normal individuals, the radiopharmaceutical will have ascended to the parasagittal region within 24 hours with simultaneous partial or complete clearance of activity from the basal cisterns and Sylvian regions. In contrast to air, the radiopharmaceutical does not normally enter the cerebral ventricles. Although the primary absorption of cerebrospinal fluid (CSF) into the blood stream occurs at the arachnoid villi, there is some evidence that a significant fraction of CSF is also absorbed across both the cerebral and spinal leptomeninges. Lesser quantities may also be absorbed across the ventricular ependyma. It is also generally held that these alternate routes of CSF absorption may assume primary importance when the major routes of the flow are pathologically obstructed
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
Approximately 65% of the administered dose is excreted by the kidneys within 24 hours and this increases to 85% in 72 hours.
- Half-life
Indium 111 decays by electron capture with a physical half-life of 67.9 hours.
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
Pregnancy Category C
Aseptic meningitis and pyrogenic reactions have been rarely (less than 0.4%) observed following cisternography
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
- Product Ingredients
Ingredient UNII CAS InChI Key Indium In-111 pentetate disodium 7UIT3ZGC8E 60662-14-8 JKGXLBAWNSPIFF-LWQDMHIUSA-I - Active Moieties
Name Kind UNII CAS InChI Key Pentetic acid unknown 7A314HQM0I 67-43-6 QPCDCPDFJACHGM-UHFFFAOYSA-N Indium cation In-111 ionic WJZ06C0H8L 131391-70-3 RJMMFJHMVBOLGY-AHCXROLUSA-N - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataIn-111 DTPA Solution 3.75 mCi/1.5mL Intrathecal Anazao Health Corporation 2012-06-19 Not applicable US 
Indium DTPA In 111 Solution 1 mCi/1mL Intrathecal Medi-Physics, Inc. dba GE Healthcare 1982-02-18 Not applicable US Additional Data Available- Application NumberApplication NumberAvailable for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct CodeAvailable for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image In-111 DTPA Indium In-111 pentetate disodium (3.75 mCi/1.5mL) Solution Intrathecal Anazao Health Corporation 2012-06-19 Not applicable US
Categories
- ATC Codes
- V09AX01 — Indium (111in) pentetic acid
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pentacarboxylic acids and derivatives. These are carboxylic acids containing exactly five carboxyl groups.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Pentacarboxylic acids and derivatives
- Direct Parent
- Pentacarboxylic acids and derivatives
- Alternative Parents
- Alpha amino acids / Trialkylamines / Carboxylic acid salts / Amino acids / Carboxylic acids / Organic zwitterions / Organic salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic acyclic compound / Alpha-amino acid / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Carbonyl group / Carboxylic acid / Carboxylic acid salt / Hydrocarbon derivative
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- 5K3UP561AX
- CAS number
- 135998-32-2
- InChI Key
- BLALCKLYSDDAOC-JWFOFJTQSA-K
- InChI
- InChI=1S/C14H23N3O10.In/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);/q;+3/p-3/i;1-4
- IUPAC Name
- (111In)indium(3+) ion 2-[bis({2-[bis(carboxymethyl)amino]ethyl})amino]acetate
- SMILES
- [111In+3].OC(=O)CN(CCN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)CC(O)=O
References
- General References
- Not Available
- External Links
- KEGG Drug
- D04527
- PubChem Compound
- 131704319
- PubChem Substance
- 347827852
- ChemSpider
- 25048228
- Drugs.com
- Drugs.com Drug Page
- FDA label
- Download (2.04 MB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Terminated Treatment Neoplasms, Brain / Tumors of the Central Nervous System 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Intrathecal 3.75 mCi/1.5mL Solution Intrathecal 1 mCi/1mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 5.71 mg/mL ALOGPS logP 0.11 ALOGPS logP -6.3 ChemAxon logS -2 ALOGPS pKa (Strongest Acidic) 1.95 ChemAxon pKa (Strongest Basic) 8.82 ChemAxon Physiological Charge -3 ChemAxon Hydrogen Acceptor Count 13 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 204.71 Å2 ChemAxon Rotatable Bond Count 16 ChemAxon Refractivity 118.96 m3·mol-1 ChemAxon Polarizability 34.91 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Drug created on November 30, 2015 12:10 / Updated on June 12, 2020 11:42